KINNATE BIOPHARMA INC's ticker is KNTE and the CUSIP is 49705R105. A total of 60 filers reported holding KINNATE BIOPHARMA INC in Q3 2023. The put-call ratio across all filers is 0.76 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $2,042,362 | -90.1% | 674,047 | -79.5% | 0.00% | -100.0% |
| Q1 2023 | $20,579,862 | +61.6% | 3,292,778 | +57.7% | 0.00% | 0.0% |
| Q4 2022 | $12,738,490 | -56.1% | 2,088,277 | -14.1% | 0.00% | -66.7% |
| Q3 2022 | $29,040,000 | +5.0% | 2,430,102 | +10.8% | 0.00% | 0.0% |
| Q2 2022 | $27,658,000 | +70.1% | 2,193,316 | +51.9% | 0.00% | +200.0% |
| Q1 2022 | $16,262,000 | -56.1% | 1,444,304 | -31.0% | 0.00% | -66.7% |
| Q4 2021 | $37,080,000 | -23.2% | 2,092,523 | -0.2% | 0.00% | -25.0% |
| Q3 2021 | $48,282,000 | -1.5% | 2,097,346 | -0.4% | 0.00% | 0.0% |
| Q2 2021 | $49,005,000 | -24.7% | 2,105,021 | -1.2% | 0.00% | -33.3% |
| Q1 2021 | $65,101,000 | -30.8% | 2,131,648 | -13.0% | 0.01% | -25.0% |
| Q4 2020 | $94,093,000 | – | 2,450,135 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 9,671,643 | $384,738,000 | 41.79% |
| Foresite Capital Management V, LLC | 875,001 | $34,808,000 | 25.78% |
| Vida Ventures Advisors, LLC | 2,747,074 | $109,279,000 | 22.43% |
| VR Adviser, LLC | 1,473,014 | $58,596,000 | 8.62% |
| RA Capital Management | 3,593,052 | $142,932,000 | 2.00% |
| Logos Global Management LP | 569,602 | $22,659,000 | 1.94% |
| Boxer Capital, LLC | 1,064,665 | $42,352,000 | 1.36% |
| Orbimed Advisors | 3,847,929 | $153,071,000 | 1.34% |
| HARVARD MANAGEMENT CO INC | 498,001 | $19,810,000 | 1.07% |
| DAFNA Capital Management LLC | 68,121 | $2,710,000 | 0.81% |